Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

57.71
+10.9223.34%
Post-market: 57.31-0.4050-0.70%19:59 EST
Volume:7.07M
Turnover:395.13M
Market Cap:7.84B
PE:-4.73K
High:59.15
Open:47.39
Low:45.09
Close:46.79
52wk High:59.15
52wk Low:9.57
Shares:135.81M
Float Shares:118.91M
Volume Ratio:2.06
T/O Rate:5.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0122
EPS(LYR):-0.0122
ROE:8.67%
ROA:4.87%
PB:16.82
PE(LYR):-4,733.04

Loading ...

Arrowhead Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Nov 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 20

Arrowhead price target raised to $48 from $27 at Goldman Sachs

TIPRANKS
·
Nov 20

Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says

MT Newswires Live
·
Nov 20

RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 19

Arrowhead Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 19

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 19

Arrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities

TIPRANKS
·
Nov 19

Arrowhead Pharmaceuticals : Piper Sandler Raises Target Price to $70 From $45

THOMSON REUTERS
·
Nov 19

U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology

Reuters
·
Nov 19

Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA

TIPRANKS
·
Nov 19

Sector Update: Health Care Stocks Higher Tuesday Afternoon

MT Newswires Live
·
Nov 19

Arrowhead Pharmaceuticals Says Wholesale Acquisition Cost Price of Redemplo Is $60,000

THOMSON REUTERS
·
Nov 19

Arrowhead Pharmaceuticals Shares up 7.4% After FDA Approval for Genetic Disorder Drug

THOMSON REUTERS
·
Nov 19

Arrowhead Pharmaceuticals - Redemplo Will Be Available in U.S. Before Year-End

THOMSON REUTERS
·
Nov 19

Arrowhead Pharmaceuticals Announces FDA Approval of Redemplo® (Plozasiran) to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
Nov 19

Arrowhead’s plozasiran approved by FDA in familial chylomicronemia syndrome

TIPRANKS
·
Nov 19

US FDA approves Arrowhead's genetic disorder drug

Reuters
·
Nov 19

FDA Approves Redemplo to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome- Website

THOMSON REUTERS
·
Nov 19

Arrowhead Pharmaceuticals Shares Halted, Pending Material News Release

MT Newswires Live
·
Nov 19